Results 41 to 50 of about 38,769 (305)
Journal of Clinical and Translational Science, 2022 OBJECTIVES/GOALS: Clinical trials of SGLT2 inhibitors in patients with heart failure (HF) have confirmed a reduction in hospitalization and death. Adoption of novel therapeutics has been slower in Black and female patients. We investigated utilization of
Apoorva Gangavelli +5 more
doaj +1 more source
Chances and risks of SGLT2 inhibitors [PDF]
Naunyn-Schmiedeberg's Archives of Pharmacology, 2011 Type II diabetes mellitus (T2DM) is characterised by relative insulin deficiency caused by resistance of important target organs like liver and skeletal muscle towards insulin. During the course of the disease, pancreatic insulin production becomes decreased, and absolute insulin deficiency results (Kahn 2003).
openaire +2 more sources
The effects of novel SGLT2 inhibitors on intestinal smooth muscle activity
, 2021 Due to their unique mechanism of action, inhibitors of the sodium-glucose cotransporter type 2, in addition to glycemic and metabolic effects, have the ability to exert an inhibitory effect on various aspects of the pathogenesis of micro- and ...
Abilkassym, Dauren
core
Could SGLT2 Inhibitors Improve Exercise Intolerance in Chronic Heart Failure? [PDF]
, 2022 Despite the constant improvement of therapeutical options, heart failure (HF) remains associated with high mortality and morbidity. While new developments in guideline-recommended therapies can prolong survival and postpone HF hospitalizations, impaired ...
Voorrips, Suzanne N. +14 more
core +1 more source
Advanced Science, EarlyView.In renal calcium oxalate stone formation, G6PC downregulation leads to lactate accumulation. This lactate mediates CBP/p300‐dependent lactylation of SNAIL1 at K206, promoting its nuclear translocation. Nuclear SNAIL1 activates the TGF‐β/SMAD3 pathway, driving epithelial‐mesenchymal transition and fibrosis, which ultimately facilitates crystal ...
Kai Liu +16 more
wiley +1 more source
SGLT2 inhibitors in cardiovascular medicine [PDF]
European Heart Journal - Cardiovascular Pharmacotherapy, 2021 Varzideh, Fahimeh +2 more
openaire +3 more sources
, 2015 Jochen SeufertDepartment of Endocrinology and Diabetology, Clinic for Internal Medicine II, Freiburg University Hospital, Freiburg, GermanyAbstract: Despite the availability of a great variety of medications, a significant proportion of people with type ...
Seufert, Jochen, Seufert J
core +1 more source
SGLT2 Inhibitors and Ketone Metabolism in Heart Failure [PDF]
, 2022 Sodium-glucose cotransporter-2 (SGLT2) inhibitors have emerged as powerful drugs that can be used to treat heart failure (HF) patients, both with preserved and reduced ejection fraction and in the presence or absence of type 2 diabetes.
Voorrips, Suzanne N. +6 more
core +1 more source
Advanced Science, EarlyView.Dual targeting of ANGPTL3 and IL‐33/ST2 attenuates diabetic kidney disease by reprogramming lipid–inflammatory crosstalk. This strategy reduces renal lipotoxicity, suppresses inflammatory activation, and limits fibrotic remodeling, thereby preserving kidney structure and function and highlighting a mechanism‐guided therapeutic approach for metabolic ...
Zhuojin Li +8 more
wiley +1 more source
Sodium-Glucose Linked Transporter-2 Inhibitors in Chronic Kidney Disease
The Scientific World Journal, 2015 SGLT2 inhibitors are new antihyperglycaemic agents whose ability to lower glucose is directly proportional to GFR. Therefore, in chronic kidney disease (CKD) the blood glucose lowering effect is reduced.
L. Zanoli +6 more
doaj +1 more source